EndoSphere to Showcase its Satisphere™ Device at MTI Europe

EndoSphere selected among the Medical Device Industry’s Technology Leaders.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The premier and longest-running medtech industry partnering event in Europe.

London (PRWEB) September 14, 2012

EndoSphere Inc. is pleased to announce that it has been selected to present at the 15th Annual MedTech Investing (MTI) Europe Conference, which will take place September 19th - 20th at the Kings Fund in London. MTI Europe is the premier and longest-running medtech industry partnering event in Europe according to Campden Conferences.

EndoSphere was hand-selected by Campden as one of 35 companies to showcase the latest innovations and investment opportunities in the medical technology industry. EndoSphere’s intellectual property portfolio includes 29 issued and pending U.S. and international patents. The company’s flagship product, the Satisphere™ System, is a noninvasive treatment for one of the world's largest health issues: metabolic diseases including obesity and type II diabetes. The Satisphere System is an endoscopically-insertable device that improves the regulation of appetite and satiety by using the body’s natural physiology. Treatment using the Satisphere device is incisionless, reversible and repeatable. Clinical studies have shown that the Satisphere System enables obese patients to achieve significant weight loss without invasive surgery or medication. The device has received CE Mark regulatory approval for commercialization in 31 countries.

Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that 35 percent of Americans are obese today. More than 400 million people in the U.S. and Europe collectively suffer from being overweight or obese. Annual costs attributed to obesity and its co-morbidities have been estimated at $147 billion.

MTI Europe will feature panels, roundtable discussions, one-to-one meetings, and presentations featuring medtech industry experts from Medtronic, Stryker Europe, ACIDIM, Gilde Healthcare Partners, Philips Healthcare, University of Cambridge, Nestlé Health Sciences, Abingworth, MedC Partners, and other industry leaders. Discussion topics will address industry dynamics and innovation, the venture capitalist cycle and the evolution of partnering, key considerations for conducting business in European markets, medtech investment opportunities, cost-effectiveness in healthcare, opportunities in emerging markets, the changing regulatory framework, and strategies to bring products to markets.

According to Campden, last year’s MTI Europe Conference in Switzerland was attended by an estimated 200 delegates from 20 different countries representing leading investment funds, medical technology companies, and major healthcare corporations.

About EndoSphere Inc.

EndoSphere is a pioneer of endoscopically-insertable medical technologies for the treatment of metabolic diseases including obesity and type II diabetes. The company holds 29 issued and pending U.S. and international patents. EndoSphere is a portfolio company of Broadline Capital, Ohio TechAngel Funds II and III, Co-Investment Fund, Glengary LLC, Physician Investment Group, EI Millstream Investment LLC, North Coast Angel Fund II, and QCA First Fund III. For more information, visit: http://www.endosphereinc.com.


Contact